Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06156215 · ClinicalTrials.gov registry record · NA
PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 919
- Enrollment target
NCT06156215: Completed NA study, sponsored by University of California, San Francisco.
NCT06156215 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 919 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06156215, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 919 participants
- Enrollment target
Study Summary
The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are: * does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? * does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? * considering recent national changes to funding and availability of updated vaccines, the investigators will examine the effects of these changes on vaccine acceptance and uptake in ED populations. Specifically, they will stratify EDs and ED patients according to the ED availability of vaccines, and they will also examine whether costs and availability of vaccines are a deterrent to patient acceptance and uptake of vaccines
Primary Outcome
Our primary outcome is booster vaccine uptake (at any vaccination location) within 30 days after participants' index ED visit, comparing Intervention M arm with Control
Interventions
- BEHAVIORAL Vaccine Messaging
- BEHAVIORAL Vaccine Acceptance Question
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 919 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2024-08-18 |
| Phase | NA |
What the finished NCT06156215 record still lists
NCT06156215 is an interventional study that assigns participants to a tested intervention. The registered 919 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Vaccine Messaging is the first listed.
NCT06156215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06156215 about?
NCT06156215 is a clinical study titled "PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED". The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are: * does the intervention of vaccine messaging increase booster vacci...
What is the current status of trial NCT06156215?
This trial is currently completed. It is a NA study. The enrollment target is 919 participants. The study started on 2024-01-19. Estimated completion is 2024-08-18.
What interventions are being tested in trial NCT06156215?
The interventions under investigation include: Vaccine Messaging (BEHAVIORAL), Vaccine Acceptance Question (BEHAVIORAL).
Who is sponsoring clinical trial NCT06156215?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06156215's enrollment target sits among peer trials
919 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
- NCT07174336 · 920 participants · Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI